Marina Sousa Gomes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Sousa Gomes has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Paula Pinheiro
Department of Obstetrics and Gynecology, Alto Minho Local Healthcare Unit, Viana do Castelo, Portugal
6 shared publicationsVera Trocado
Department of Obstetrics and Gynecology, Alto Minho Local Healthcare Unit, Viana do Castelo, Portugal
3 shared publicationsAgostinho Carvalho
2 shared publicationsDiana Arteiro
A Department of Obstetrics and Gynecology , Local Unit of Health in Alto Minho , Viana do Castelo , Portugal
2 shared publicationsJoana Pereira
2 shared publicationsMariana Carlos-Alves
A Department of Obstetrics and Gynecology , Local Unit of Health in Alto Minho , Viana do Castelo , Portugal
2 shared publications
Latest Publications
- Open Access
- 22 December 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (12) , e240361
Double inferior vena cava in gynaecological oncology surgery
- 22 December 2020
- Published by BMJ in BMJ Case Reports
- Vol. 13 (12) , e240361
Open AccessDouble inferior vena cava in gynaecological oncology surgery
- 4 September 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (3) , 457-463
Monochorionic Twin Discordance for Horseshoe Lung and Tricuspid Atresia
The horseshoe lung is a congenital malformation in which the bases of the right and the left lung are fused. Case report: We describe a monochorionic twin gestation with malformation discordance. T...
- 4 September 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (3) , 457-463
Monochorionic Twin Discordance for Horseshoe Lung and Tricuspid Atresia
The horseshoe lung is a congenital malformation in which the bases of the right and the left lung are fused. Case report: We describe a monochorionic twin gestation with malformation discordance. T...
- 10 August 2020
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 302 (5) , 1081-1086
Vulvar Hailey–Hailey disease treated with low-dose naltrexone: case report and literature review
Purpose To report a case of vulvar familial benign pemphigus, or Hailey–Hailey disease, treated successfully with low-dose naltrexone and to review the current literature. Methods We report a case of a 71-year-old white woman with vulvar Hailey–Hailey disease recalcitrant to topical corticosteroids. After treatment with low-dose naltrexone, 3 mg nightly was initiated, the lesions began to heal and 5 months later her skin showed no lesions. A literature review on the use of low-dose naltrexone for Hailey–Hailey disease was performed. We searched the PubMed/MEDLINE databases for previous case reports using the key words ‘‘Pemphigus, Benign Familial’’ and ‘‘naltrexone”. Results We found 35 more cases of Hailey–Hailey disease treated with naltrexone, showing promising results, reported until January 2020, with no major adverse effects. Conclusion Low-dose naltrexone may represent a cost-effective and successful treatment modality in nongeneralized Hailey–Hailey disease without serious adverse effects. Future prospective studies are needed to investigate this interesting therapeutic option.
- 10 August 2020
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 302 (5) , 1081-1086
Vulvar Hailey–Hailey disease treated with low-dose naltrexone: case report and literature review
Purpose To report a case of vulvar familial benign pemphigus, or Hailey–Hailey disease, treated successfully with low-dose naltrexone and to review the current literature. Methods We report a case of a 71-year-old white woman with vulvar Hailey–Hailey disease recalcitrant to topical corticosteroids. After treatment with low-dose naltrexone, 3 mg nightly was initiated, the lesions began to heal and 5 months later her skin showed no lesions. A literature review on the use of low-dose naltrexone for Hailey–Hailey disease was performed. We searched the PubMed/MEDLINE databases for previous case reports using the key words ‘‘Pemphigus, Benign Familial’’ and ‘‘naltrexone”. Results We found 35 more cases of Hailey–Hailey disease treated with naltrexone, showing promising results, reported until January 2020, with no major adverse effects. Conclusion Low-dose naltrexone may represent a cost-effective and successful treatment modality in nongeneralized Hailey–Hailey disease without serious adverse effects. Future prospective studies are needed to investigate this interesting therapeutic option.
- 6 February 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (6) , E9
Twin Anemia Polycythemia Sequence
Physical examination at birth of monochorionic, diamniotic twins born at 31 weeks of gestation showed a pallid first twin and a plethoric second twin. Findings on transabdominal ultrasonography that had been performed at 30 weeks of gestation were suggestive of twin anemia polycythemia sequence.
- 6 February 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (6) , E9
Twin Anemia Polycythemia Sequence
Physical examination at birth of monochorionic, diamniotic twins born at 31 weeks of gestation showed a pallid first twin and a plethoric second twin. Findings on transabdominal ultrasonography that had been performed at 30 weeks of gestation were suggestive of twin anemia polycythemia sequence.
- 9 July 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (7) , e230987
Lung migration of contraceptive Implanon NXT
- 9 July 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (7) , e230987
Lung migration of contraceptive Implanon NXT
- 1 March 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 234, e90
Impact of nulliparous women's pre-pregnancy weight and risk of laceration at birth
- 1 March 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 234, e90
Impact of nulliparous women's pre-pregnancy weight and risk of laceration at birth
- 1 March 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 234, e95
Ectopic pregnancy – Six years experience in a secondary hospital
- 1 March 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 234, e95
Ectopic pregnancy – Six years experience in a secondary hospital
- 9 November 2018
- Published by Morressier GmbH
09 - TREATMENT OF VULVAR HAILEY-HAILEY DISEASE WITH LOW-DOSE NALTREXONE
Problem statement: Familial benign pemphigus, or Hailey-Hailey disease (HHD), is a rare and severe autosomal dominant dermatosis characterized by chronic recurrent vesicles, erosions, and maceration in intertriginous areas. Despite the multiple therapies, such as topical and systemic corticosteroids, systemic immunomodulators, topical and systemic retinoids and laser, HHD can be
- 9 November 2018
- Published by Morressier GmbH
09 - TREATMENT OF VULVAR HAILEY-HAILEY DISEASE WITH LOW-DOSE NALTREXONE
Problem statement: Familial benign pemphigus, or Hailey-Hailey disease (HHD), is a rare and severe autosomal dominant dermatosis characterized by chronic recurrent vesicles, erosions, and maceration in intertriginous areas. Despite the multiple therapies, such as topical and systemic corticosteroids, systemic immunomodulators, topical and systemic retinoids and laser, HHD can be
- 9 March 2018
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 38 (6) , 745-749
Intrapartum synthetic oxytocin and breastfeeding: a retrospective cohort study
Non-pulsatile oxytocin given during labour can negatively affect breastfeeding. The aim of this study was to assess whether intrapartum oxytocin administration has any effect on breastfeeding. Secondly, to assess whether some maternal or neonatal variables influence breastfeeding. A retrospective cohort study was done, comparing two groups: women exposed (n = 101) and not exposed to oxytocin (n = 100) during labour. Women with caesarean section, vacuum extraction/forceps, twin pregnancy, breech presentation, premature neonates and with an Apgar score p = .038). At three months’ postpartum, 26.7% women in the exposed group versus 14% in the non-exposed group were not breastfeeding (p = .035). This result was not statistically significant when adjusting for possible confounders. High pregestational body mass index was the best predictor of an impaired third month’s postpartum breastfeeding (OR =0.901, CI: 0.835–0.972; p = .007). Intrapartum oxytocin administration could inhibit first hour breastfeeding. A novel association was detected, pregestational body mass index was a predictor of impaired breastfeeding at three months, possibly confounding the oxytocin effect. Additional prospective studies are needed to investigate potential associations between intrapartum oxytocin and breastfeeding.
- 9 March 2018
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 38 (6) , 745-749
Intrapartum synthetic oxytocin and breastfeeding: a retrospective cohort study
Non-pulsatile oxytocin given during labour can negatively affect breastfeeding. The aim of this study was to assess whether intrapartum oxytocin administration has any effect on breastfeeding. Secondly, to assess whether some maternal or neonatal variables influence breastfeeding. A retrospective cohort study was done, comparing two groups: women exposed (n = 101) and not exposed to oxytocin (n = 100) during labour. Women with caesarean section, vacuum extraction/forceps, twin pregnancy, breech presentation, premature neonates and with an Apgar score p = .038). At three months’ postpartum, 26.7% women in the exposed group versus 14% in the non-exposed group were not breastfeeding (p = .035). This result was not statistically significant when adjusting for possible confounders. High pregestational body mass index was the best predictor of an impaired third month’s postpartum breastfeeding (OR =0.901, CI: 0.835–0.972; p = .007). Intrapartum oxytocin administration could inhibit first hour breastfeeding. A novel association was detected, pregestational body mass index was a predictor of impaired breastfeeding at three months, possibly confounding the oxytocin effect. Additional prospective studies are needed to investigate potential associations between intrapartum oxytocin and breastfeeding.
- 11 February 2018
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 32 (14) , 2418-2428
Thrombolysis in pregnancy: a literature review
Background: Changes in the coagulation system during pregnancy and puerperium produce a physiological hypercoagulable state. These changes are thought to be the cause of the higher rates of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and mechanical prosthetic valve thrombosis (PVT) during pregnancy. Thrombolysis can be a treatment option in this case. However, there are no available data from randomized controlled trials in pregnant patients and information about the security of thrombolytics in pregnancy is missing. Objective: The aim of this review is to summarize the available data regarding the use of thrombolytic agents in pregnancy, describing maternal and fetal outcomes. Methods: A systematic review was performed, searching the electronic database MEDLINE for relevant studies published up to April 2017. The search included MeSH terms “thrombolytic therapy” OR “fibrinolysis” OR “streptokinase” OR “tissue plasminogen activator” AND “pregnancy”. All publications that reported the use of a thrombolytic agent for DVT, PE, stroke or PVT in pregnancy were included in the review. Data on the type and total dose of the thrombolytic agent, gestational week, outcome of mothers and children, preterm delivery and bleeding complications were described. Results: Sixty-five articles have been published describing outcomes in 141 pregnant women with serious thrombotic events. There have been no randomized trials involving the use of thrombolytics in pregnancy. Only one prospective study was found. Four maternal deaths (2.8%), 12 major bleeding episodes (8.5%), 13 mild/moderate bleeding episodes (9.2%), two fetal death (1.4%), one child death (0.7%), nine miscarriages (6.4%), and 14 preterm delivery (9.9%) were described. Conclusions: The risk of using thrombolytics in pregnancy seems reasonable taking into account the risk of death in a life-threatening event, with the majority of cases presented in this article resulting in encouraging outcomes. The complication rate of thrombolytic treatment does not seem higher in pregnant women than in the nonpregnant. Poor fetal outcome occurred in mothers with poor prognosis. Specific consensus recommendations are needed in the use of thrombolytics in pregnancy.
- 11 February 2018
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 32 (14) , 2418-2428
Thrombolysis in pregnancy: a literature review
Background: Changes in the coagulation system during pregnancy and puerperium produce a physiological hypercoagulable state. These changes are thought to be the cause of the higher rates of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and mechanical prosthetic valve thrombosis (PVT) during pregnancy. Thrombolysis can be a treatment option in this case. However, there are no available data from randomized controlled trials in pregnant patients and information about the security of thrombolytics in pregnancy is missing. Objective: The aim of this review is to summarize the available data regarding the use of thrombolytic agents in pregnancy, describing maternal and fetal outcomes. Methods: A systematic review was performed, searching the electronic database MEDLINE for relevant studies published up to April 2017. The search included MeSH terms “thrombolytic therapy” OR “fibrinolysis” OR “streptokinase” OR “tissue plasminogen activator” AND “pregnancy”. All publications that reported the use of a thrombolytic agent for DVT, PE, stroke or PVT in pregnancy were included in the review. Data on the type and total dose of the thrombolytic agent, gestational week, outcome of mothers and children, preterm delivery and bleeding complications were described. Results: Sixty-five articles have been published describing outcomes in 141 pregnant women with serious thrombotic events. There have been no randomized trials involving the use of thrombolytics in pregnancy. Only one prospective study was found. Four maternal deaths (2.8%), 12 major bleeding episodes (8.5%), 13 mild/moderate bleeding episodes (9.2%), two fetal death (1.4%), one child death (0.7%), nine miscarriages (6.4%), and 14 preterm delivery (9.9%) were described. Conclusions: The risk of using thrombolytics in pregnancy seems reasonable taking into account the risk of death in a life-threatening event, with the majority of cases presented in this article resulting in encouraging outcomes. The complication rate of thrombolytic treatment does not seem higher in pregnant women than in the nonpregnant. Poor fetal outcome occurred in mothers with poor prognosis. Specific consensus recommendations are needed in the use of thrombolytics in pregnancy.